Industry News

- Read more about Sun Pharma, AstraZeneca come toward for marketing of heart drug ticagrelor in India
Sun Pharmaceutical Industries and AstraZeneca Pharma India (AZPIL) have entered agreement for distribution of AstraZeneca’s brand “Axcer”, a new brand of ticagrelor in India. This drug is used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012. This collaboration will provide customers access to this latest generation treatment option for ACS.
- Read more about IAP HealthPhone introduced to address malnutrition in women and children
The Indian Academy of Paediatrics (IAP) in partnership with HealthPhone, Ministry of Women and Child Development (MWCD), Government of India and UNICEF, announced launch of the IAP HealthPhone programme, the world's largest digital mass education programme to face the challenge of malnutrition in women and children, at the national-level in India. The programme will achieve its objectives by widely promoting and distributing four re-edited videos from the Poshan series, jointly produced by MWCD and UNICEF in 18 Indian languages. The Poshan videos address issues of status of women, the care of pregnant women and children under two, breastfeeding and the importance of balanced diet, health and simple changes in nutritional care practices that can notably enhance nutrition levels.
- Read more about Par Pharma launch Cortisporin-TC otic suspension to treat otitis externa
Par Specialty Pharmaceuticals, a division of Par Pharmaceutical, Inc., announced the launch of Cortisporin-TC otic suspension (colistin sulfate - neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic suspension).
- Read more about Glenmark receive USFDA approval to sell Rufinamide
Glenmark Pharmaceuticals granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.
- Read more about DeNovo associate with START to use CTCs for whole genome sequencing
DeNovo Sciences, Inc., an innovator of cutting edge products of liquid biopsy, sign an agreement with START (South Texas Accelerated Research Therapeutics), a San Antonio based phase I medical oncology programme, one of the world’s largest of its kind with clinical trial sites on three continents. As per agreement, START will collect blood samples of cancer patients and use DeNovo instruments and reagents for circulating tumour cells (CTC) enrichment and purification. This will further will then be sent to a large genomics lab for whole genome sequencing. In addition, START and DeNovo have signed a separate agreement to test the ability of Denovo CTC platform to capture CTCs for use in patient derived xenograft (PDX) mice models for drug discovery and biomarker development purposes.
- Read more about 19 pharma companies received final warning from NPPA for registeration with IPDMS
National Pharmaceutical Pricing Authority (NPPA) given a final opportunity to companies to register with Integrated Pharmaceutical Database Management System (IPDMS). 19 companies out of Top 100, which have not yet registered with IPDMS as on 01.06.2015.
- Read more about Vanda Pharma honoured with 2015 Industry Innovation Award from NORD for development of Hetlioz
Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs., has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of company's work in developing Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). This award was presented to Vanda at the 2015 Portraits of Courage Gala in Washington D.C. on 18th May.
- Read more about Eli Lilly's Humalog 200 units/mL KwikPen approved by USFDA
US Food and Drug Administration (FDA) has approved Eli Lilly and Company Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro 100 units/mL) Humalog U-200 KwikPen is used to improve glycemic control in people with type 1 and type 2 diabetes.
- Read more about US FDA approves Actavis' Viberzi to treat irritable bowel syndrome with diarrhea in adults
The Food and Drug Administration (FDA) has approved Actavis' Viberzi (eluxadoline) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).
IBS-D is a multifactorial disorder marked by recurrent abdominal pain or discomfort and altered bowel function that affects as many as 15 million adult Americans, impacting about twice as many women as men. There are few treatment options available for IBS-D, particularly options that relieve both the diarrhea and abdominal pain associated with IBS-D.
- Read more about Aurobindo Pharma wants US FDA tentative approval for generic dolutegravir for treatment of HIV
ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced that Aurobindo Pharma, has submitted to the Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for tentative approval, for HIV treatment. Upon receiving tentative approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay (dolutegravir) for sale in the United States.

[adsense:336x280:8701650588]